Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash & Equivalents (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Cash & Equivalents for 15 consecutive years, with $340.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 2.55% year-over-year to $340.2 million, compared with a TTM value of $340.2 million through Sep 2025, down 2.55%, and an annual FY2024 reading of $233.0 million, down 10.07% over the prior year.
  • Cash & Equivalents was $340.2 million for Q3 2025 at Neurocrine Biosciences, up from $264.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $396.3 million in Q1 2024 and bottomed at $111.6 million in Q1 2023.
  • Average Cash & Equivalents over 4 years is $270.0 million, with a median of $278.8 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents soared 255.11% in 2024, then tumbled 51.02% in 2025.
  • Year by year, Cash & Equivalents stood at $311.1 million in 2021, then decreased by 16.71% to $259.1 million in 2023, then dropped by 10.07% to $233.0 million in 2024, then surged by 46.01% to $340.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for NBIX at $340.2 million in Q3 2025, $264.0 million in Q2 2025, and $194.1 million in Q1 2025.